Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Cambrex's Business Segments
Cambrex's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q3 FY2019
Reportable Segments
3
Largest Segment
Drug Substance
Total Revenue
$ 149
Regions Reported
-
Revenue Share by Reportable Segment - Q3 FY2019
- Drug Substance69.7%
- Early Stage Development and Testing15.2%
- Drug Product15.1%
Revenue by Reportable Segment - Q3 FY2019
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Drug Substance | $ 104 | 69.7% |
| Early Stage Development and Testing | $ 23 | 15.2% |
| Drug Product | $ 22 | 15.1% |
Revenue by Product & Service Category - Q3 FY2019
- Product79.9%
- Multi Use Products43.4%
- Single Use Products36.5%
- Service18.4%
- Service Revenue18.4%
Revenue by Product & Service Category - Q3 FY2019
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 119 | 79.9% |
| Multi Use Products | $ 65 | 43.4% |
| Single Use Products | $ 54 | 36.5% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Cambrex
Cambrex Corporation is a global pharmaceutical contract development and manufacturing organization (CDMO) that specializes in the development and production of active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs) for the biopharmaceutical industry. The company was founded in 1981 and is headquartered in East Rutherford, New Jersey, United States.
Cambrex's services cover a wide range of areas, including custom development and manufacture of APIs, analytical development and testing, formulation development, and finished dosage form manufacturing. The company works with small to mid-sized biopharmaceutical companies, as well as multinational pharmaceutical corporations.
The company operates in three business segments: Small Molecules, Biologics, and Drug Product. The Small Molecules segment provides custom development and manufacturing services for APIs that are used in a variety of therapeutic areas, including oncology, anti-viral, anti-inflammatory, and cardiovascular. The Biologics segment specializes in the development and manufacture of biologic APIs, such as monoclonal antibodies, recombinant proteins, and vaccines. The Drug Product segment provides finished dosage form manufacturing, including capsule filling and tablet compression.
Cambrex has a strong global presence and operates a network of facilities in the United States, Europe, and Asia-Pacific. Its facilities are equipped with advanced technology and equipment, enabling the company to provide high-quality services to its customers. The company has a robust quality management system and is certified by regulatory agencies such as the United States Food and Drug Administration (FDA) and European Medicines Agency (EMA).
The company has a strong track record of growth, driven by its focus on providing high-quality services to its customers. Cambrex has made strategic acquisitions, such as Halo Pharma in 2018, to expand its capabilities and strengthen its position in the CDMO industry. It has also made significant investments in research and development to develop innovative solutions for its customers.
In summary, Cambrex Corporation is a leading global CDMO that provides custom development and manufacturing services for APIs and finished dosage forms to the biopharmaceutical industry. With its strong global presence, advanced technology and equipment, and robust quality management system, Cambrex is well-positioned for further growth and success in the future.
Cambrex's services cover a wide range of areas, including custom development and manufacture of APIs, analytical development and testing, formulation development, and finished dosage form manufacturing. The company works with small to mid-sized biopharmaceutical companies, as well as multinational pharmaceutical corporations.
The company operates in three business segments: Small Molecules, Biologics, and Drug Product. The Small Molecules segment provides custom development and manufacturing services for APIs that are used in a variety of therapeutic areas, including oncology, anti-viral, anti-inflammatory, and cardiovascular. The Biologics segment specializes in the development and manufacture of biologic APIs, such as monoclonal antibodies, recombinant proteins, and vaccines. The Drug Product segment provides finished dosage form manufacturing, including capsule filling and tablet compression.
Cambrex has a strong global presence and operates a network of facilities in the United States, Europe, and Asia-Pacific. Its facilities are equipped with advanced technology and equipment, enabling the company to provide high-quality services to its customers. The company has a robust quality management system and is certified by regulatory agencies such as the United States Food and Drug Administration (FDA) and European Medicines Agency (EMA).
The company has a strong track record of growth, driven by its focus on providing high-quality services to its customers. Cambrex has made strategic acquisitions, such as Halo Pharma in 2018, to expand its capabilities and strengthen its position in the CDMO industry. It has also made significant investments in research and development to develop innovative solutions for its customers.
In summary, Cambrex Corporation is a leading global CDMO that provides custom development and manufacturing services for APIs and finished dosage forms to the biopharmaceutical industry. With its strong global presence, advanced technology and equipment, and robust quality management system, Cambrex is well-positioned for further growth and success in the future.
Cambrex Corporation is a significant player in the pharmaceutical manufacturing sector, particularly known for its production of small molecule Active Pharmaceutical Ingredients (APIs), advanced intermediates, and finished dosage forms (FDFs). The company is structured into three main business segments: Contract Development and Manufacturing Organization (CDMO), Generic API, and Proprietary Products. Each segment has distinct offerings tailored to cater to the diverse needs of its customers in the pharmaceutical and biotechnology industries.
1. CDMO Segment:
The CDMO segment stands out by providing comprehensive contract development and manufacturing services to pharmaceutical and biopharmaceutical firms. This segment focuses on the entire lifecycle of product development, offering an array of services that includes:
- Process Development: Cambrex assists clients in optimizing their manufacturing processes. This includes everything from initial concept through to the established processes used for commercial production, emphasizing efficiency, scalability, and regulatory compliance.
- Analytical Development and Testing: Cambrex offers extensive analytical development services, including method development and validation, stability studies, and quality control testing. These rigorous testing protocols ensure that products meet both regulatory standards and client specifications.
- Clinical and Commercial Manufacturing: Cambrex supports clients at every stage of their products lifecycle, from small-scale clinical trials to large-scale commercial production. This flexibility allows clients to scale their manufacturing processes according to market demands.
- Regulatory Support: Navigating regulatory requirements is critical for pharmaceutical companies. Cambrex provides expertise in regulatory strategies and submission processes to facilitate smooth market entry for new drugs.
- Validation Services: Ensuring that manufacturing processes and equipment operate as intended is vital for compliance and product quality. Cambrex conducts comprehensive validation studies, including process validation, cleaning validation, and equipment qualification.
- End-to-End Solutions: The CDMO segment is characterized by its end-to-end service offering, which encompasses everything from initial stages of drug development through to final product packaging. This integrated approach enables clients to accelerate the time to market for their products.
Generic API Segment:
In the Generic API segment, Cambrex is dedicated to producing a wide range of high-quality generic Active Pharmaceutical Ingredients. The key highlights include:
- Broad Portfolio: Cambrex offers a vast array of generic APIs including well-known products like Ibuprofen, Acetaminophen, and Sertraline. This diverse portfolio allows the company to cater to a wide range of therapeutic areas.
- Custom Synthesis Services: Recognizing the unique needs of clients, Cambrex provides custom synthesis services. This means they can create specific molecules and compounds tailored to customer specifications, enhancing flexibility and responsiveness in production cycles.
- Global Reach: Cambrexs generic APIs are supplied to manufacturers around the world, ensuring widespread availability and support for various markets.
Proprietary Products Segment:
The Proprietary Products segment highlights Cambrexs own branded products, sold through a global distribution network. This segment includes:
- Finished Dosage Forms (FDFs): Cambrex produces a variety of FDFs, which may include tablets, capsules, and injectable forms. These products often include controlled substances and drugs used in oncology, highlighting the company’s capability in managing complex formulations.
- Niche Pharmaceuticals: Cambrex focuses on specialized markets by offering niche pharmaceuticals that cater to specific medical needs, often where there is less competition.
- Custom Drug Product Manufacturing: Similar to its CDMO capabilities, Cambrex offers custom drug formulation and manufacturing services. This can involve tailored packaging solutions and dosage forms, allowing for greater customization for clients.
- Analytical Development Services: Alongside product manufacturing, the Proprietary Products segment includes analytical development services that ensure the quality and efficacy of the proprietary products before market release.
In summary, Cambrex Corporations comprehensive range of services and products across its three business segments empowers clients in the pharmaceutical and biotechnology sectors. From contract development and manufacturing to high-quality generic APIs and proprietary FDFs, Cambrex plays a pivotal role in enabling pharmaceutical companies to expedite drug development and meet market needs effectively. Its commitment to quality, customization, and regulatory compliance positions Cambrex as a trusted partner in the global healthcare supply chain.
1. CDMO Segment:
The CDMO segment stands out by providing comprehensive contract development and manufacturing services to pharmaceutical and biopharmaceutical firms. This segment focuses on the entire lifecycle of product development, offering an array of services that includes:
- Process Development: Cambrex assists clients in optimizing their manufacturing processes. This includes everything from initial concept through to the established processes used for commercial production, emphasizing efficiency, scalability, and regulatory compliance.
- Analytical Development and Testing: Cambrex offers extensive analytical development services, including method development and validation, stability studies, and quality control testing. These rigorous testing protocols ensure that products meet both regulatory standards and client specifications.
- Clinical and Commercial Manufacturing: Cambrex supports clients at every stage of their products lifecycle, from small-scale clinical trials to large-scale commercial production. This flexibility allows clients to scale their manufacturing processes according to market demands.
- Regulatory Support: Navigating regulatory requirements is critical for pharmaceutical companies. Cambrex provides expertise in regulatory strategies and submission processes to facilitate smooth market entry for new drugs.
- Validation Services: Ensuring that manufacturing processes and equipment operate as intended is vital for compliance and product quality. Cambrex conducts comprehensive validation studies, including process validation, cleaning validation, and equipment qualification.
- End-to-End Solutions: The CDMO segment is characterized by its end-to-end service offering, which encompasses everything from initial stages of drug development through to final product packaging. This integrated approach enables clients to accelerate the time to market for their products.
Generic API Segment:
In the Generic API segment, Cambrex is dedicated to producing a wide range of high-quality generic Active Pharmaceutical Ingredients. The key highlights include:
- Broad Portfolio: Cambrex offers a vast array of generic APIs including well-known products like Ibuprofen, Acetaminophen, and Sertraline. This diverse portfolio allows the company to cater to a wide range of therapeutic areas.
- Custom Synthesis Services: Recognizing the unique needs of clients, Cambrex provides custom synthesis services. This means they can create specific molecules and compounds tailored to customer specifications, enhancing flexibility and responsiveness in production cycles.
- Global Reach: Cambrexs generic APIs are supplied to manufacturers around the world, ensuring widespread availability and support for various markets.
Proprietary Products Segment:
The Proprietary Products segment highlights Cambrexs own branded products, sold through a global distribution network. This segment includes:
- Finished Dosage Forms (FDFs): Cambrex produces a variety of FDFs, which may include tablets, capsules, and injectable forms. These products often include controlled substances and drugs used in oncology, highlighting the company’s capability in managing complex formulations.
- Niche Pharmaceuticals: Cambrex focuses on specialized markets by offering niche pharmaceuticals that cater to specific medical needs, often where there is less competition.
- Custom Drug Product Manufacturing: Similar to its CDMO capabilities, Cambrex offers custom drug formulation and manufacturing services. This can involve tailored packaging solutions and dosage forms, allowing for greater customization for clients.
- Analytical Development Services: Alongside product manufacturing, the Proprietary Products segment includes analytical development services that ensure the quality and efficacy of the proprietary products before market release.
In summary, Cambrex Corporations comprehensive range of services and products across its three business segments empowers clients in the pharmaceutical and biotechnology sectors. From contract development and manufacturing to high-quality generic APIs and proprietary FDFs, Cambrex plays a pivotal role in enabling pharmaceutical companies to expedite drug development and meet market needs effectively. Its commitment to quality, customization, and regulatory compliance positions Cambrex as a trusted partner in the global healthcare supply chain.